Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Medidata Solutions Helps RTI International Address Evolving Research Technology Needs

Stock quotes in this article: MDSO 

As part of its growing effort to enhance the efficiency of government-funded healthcare research, Medidata Solutions recently worked with distinguished R&D and technical services institute RTI International to upgrade the technology it uses to provide statistical and data coordinating services for National Institutes of Health (NIH)-funded research. In recent years, a significantly growing share of this research has been conducted in support of biopharmaceutical development, prompting RTI to introduce new electronic data capture (EDC) and clinical data management (CDM) technology to best handle the unique data quality requirements of FDA-regulated studies.

  • “RTI required the new EDC/CDM vendor to provide a software-as-a-service (SaaS) solution that could support rapid transition from existing study databases as well as a robust knowledge transfer program to ensure our complete self-sufficiency,” said Rick Williams, senior research statistician, RTI International. “After extensive review of 20 systems, Medidata Solutions was selected and has met these requirements extremely well, along with providing the appropriate process and business support for government-funded research.”

RTI is about to kick off its sixth study using Medidata Rave, with another three to four planned for the coming year. The majority of current studies support research sponsored by the National Institute of Child Health and Human Development (NICHD).

  • “We’re very satisfied with the smooth and rapid transition of our Pelvic Floor Disorders Network studies to Medidata’s database,” said Dennis Wallace, senior research statistician, RTI International. “The use of Rave has produced a high quality of data that conforms to regulatory requirements.”

Medidata Rave is a fully hosted, web-based SaaS solution that is CFR 21 and Federal Information Systems Management Act (FISMA) compliant. Powerful, standards-based web services application programming interfaces (APIs) facilitate rapid integration to other systems to support advanced workflows, analysis, reporting and migration of data from existing clinical databases.

  • “Government-funded research has become an important part of our business as the clinical data and study conduct standards for industry, government and academia converge,” said Tarek Sherif, CEO, Medidata Solutions. “Our ability to support a prestigious organization such as RTI and the research networks it services is testament to our technical leadership in meeting those standards, as well as evidence of the ease in which government agencies can do business with us.”

Connect with Medidata:

About RTI International

RTI International is one of the world’s leading research institutes, dedicated to improving the human condition by turning knowledge into practice. Their staff of more than 2,800 provides research and technical services to governments and businesses in more than 40 countries in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy and the environment, and laboratory testing and chemical analysis. For more information, visit www.rti.org.

RTI International is a trade name of Research Triangle Institute.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs